Technology Most life sciences executives say digital delivery of drugs...

Most life sciences executives say digital delivery of drugs is the future of health

-

The world’s leading connectivity and provider of electronic solutions, Molex and, its medical device distribution subsidiary, Phillips-Mediaize, has reported the findings of the worldwide survey of pharmaceutical administrators today, evaluating their market plans, real-world insights, and perspectives on the future of digital drug delivery. These results evaluated the increasing acceptance of digitalized drug delivery, and about one-third of those who participated are already selling one or more of these drugs.

“It’s encouraging to see the groundswell of interest in digitizing drug delivery to improve patient care and produce better outcomes,” said Paul Chaffin, president of Molex. “The future of Pharma lies in the design and development of patient-focused devices that are easy to use and can collect and connect data seamlessly and securely to personalize treatment while driving increased medication adherence.”

In April, Molex, and Phillips-Medisize conducted the digital health and the future of pharmaceuticals survey, which polled 215 trained Pharma professionals in various positions and territories. All of the survey participants were investors in a variety of digital drug delivery devices, that were developed to provide patient benefits, including delivering accurate dosages, tracking use, integrating with diagnostic equipments, and recording and sharing data for electronic patients’ health records.

Digital drug delivery was rated “extremely” or “very important” to future strategies by 88% of the participants. 86% of respondents believed that Covid-19 will have a long-time effect on patient interest in self-care/remote choices. Young people are far more accessible to digital drug delivery, according to 3 out of 4 survey respondents.

All respondents found ways to enhance patient care. The top five of most promising areas are as follow:

  • Customized drug delivery to meet the needs and demands of patients (57%)
  • Encourage the use of more efficient dosing schedules (55%)
  • Assures accurate dose administration (55%)
  • Increase in dosage regimen compliance (52%)
  • Allowing patients to administer their drugs at home instead of in a clinic or hospital (48%)

67% of survey participants believed that digital options will result in “dramatically” or “notably better” patient care when possible advantages of the digitized drug delivery were compared with conventional approaches. Pharmaceutical decision-makers highlighted cost savings of outcomes by enhanced compliance (60%), improved productivity through targeting labor-intensive behavioral health support (54%), and more effective and flexible ways to provide patient care (53%), as the top possible business advantages using electronic delivery approaches.

Patients should come first to maximize compliance and improve outcomes, and this, in turn, would reduce health care costs, according to survey results. Poor patient compliance is liable for $290 billion in “ otherwise avoidable medical spending” in the United States per year, according to the New England Healthcare Initiative (NEHI). NHEI also reported that half of the 187 million Americans do not take their drugs as directed by prescribers.

Metabolism/Endocrine system disorders (64%), respiratory diseases (57%), and inflammatory/immune disorders (52%) were designated as the top 3 treatment categories with substantial potential for digital distribution, by survey participants.

About 96% of the participants noticed adoption issues, despite their positive perspective for the future of digital drug delivery, which includes data protection issues (40%), insufficient patient internet access (39%), high system and communication cost (39%), and regulatory issues (39%).

Latest news

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Duchenne Muscular Dystrophy Fails to Show Functional Improvement

Pfizer's gene therapy for Duchenne muscular dystrophy failed to improve motor function in young boys in a key late-stage...

Phase 3 Trial Results for Loqtorzi Show Positive Results in Advanced Hepatocellular Carcinoma Patients

Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show that in first-line patients suffering from advanced hepatocellular...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you